rare diseases

Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand
Biotech

BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect

BioMarin has followed through on its shift to external innovation, inking a deal to add a phase 3 enzyme replacement therapy to its pipeline.
Nick Paul Taylor May 16, 2025 8:46am
delay FDA delay

FDA delays decision on Biohaven troriluzole filing, plans adcomm

May 15, 2025 6:02am
reshuffle pipeline target reorganize shift change

Recursion streamlines pipeline following merger with Exscientia

May 5, 2025 11:00am
red tape delay stop error tie down stall

FDA misses PDUFA date for Stealth’s ultra-rare disease candidate

Apr 30, 2025 9:00am
brain money funding

Biohaven lands funding Oberland funding deal worth up to $600M

Apr 28, 2025 4:43pm
Business person contemplating how to navigate a maze made of money

Glycomine's $115M series C to fund genetic disorder ph. 2 plans

Apr 16, 2025 9:20am